Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and keeps a Neutral rating on the shares. The firm notes the company reported earnings and reiterated guidance for topline data from the Phase 3 UPSTREAM MG study in the first half of 2027. Wedbush remains interested in the potential for telitacicept to be a first-in-class BAFF/APRIL antagonist for multiple indications. Strong results from UPSTREAM MG should increase confidence in results for multiple other indications from Chinese partner RemeGen, including Sjogren’s disease. However, until Vor demonstrates efficacy in a global trial, the firm remains on the fence regarding shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High
- Vor Bio files to sell 5.34M shares of common stock for holders
- Clene, Lovesac, HDFC Bank, State Street, Vor Shock
- Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup
- Vor Bio price target lowered to $31 from $32 at H.C. Wainwright